Viking Therapeutics, Inc. (NASDAQ: VKTX) is a Healthcare company (Biotechnology) with a market capitalization of $3.4B. The Maz Rating grades it against the other companies in its sector.
Viking Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $26.88, Viking Therapeutics, Inc. trades at 5.4x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -117.3%, return on invested capital of -76.9% and a free cash flow yield of -13.5%. On the balance sheet: a debt-to-equity ratio of 0.43 and a current ratio of 7.27. Over the past 52 weeks the share price ranged from $23.82 to $43.10, with a beta of 0.65.
Viking Therapeutics, Inc. does not currently pay a dividend.
24 Wall Street analyst ratings cover the stock: 1 Strong Buy, 22 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Viking Therapeutics, Inc. (VKTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 7.13% / 30% · (Cash+Inv) / Mkt Cap (36m) 27.3% / 30% · Interest income / Revenue 401400000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 7.13% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 27.3% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 401400000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 7.13% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 27.3% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 401400000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 8.88% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 98.1% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 401400000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 25.7% / 33.33% · (Cash+ST Inv) / Total Assets 98.2% / 33.33% · (Cash+Recv) / Total Assets 98.2% / 33.33% · Interest income / Revenue 401400000.0% / 5% | Fail |
No. As of September 2026, Viking Therapeutics, Inc. (VKTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Viking Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 401400000.0% of each dividend: Viking Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.